Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
On August 9, 2023, the U.S. Food and Drug Administration (FDA) approved pralseti···【more】
Release date：2026-01-15Recommended：21
Pralsetinib is indicated for the treatment of patients with metastatic (spread) ···【more】
Release date：2026-01-15Recommended：28
Pralsetinib is indicated for the treatment of patients with advanced or metastat···【more】
Release date：2026-01-15Recommended：29
As a novel AKT inhibitor, the drug interactions of capivasertib represent a crit···【more】
Release date：2026-01-13Recommended：30
Although capivasertib offers a new treatment option for specific cancers, its ef···【more】
Release date：2026-01-13Recommended：29
Do not take other medications unless you have discussed them with your doctor. T···【more】
Release date：2026-01-13Recommended：35
This medicine may affect your blood glucose levels. If you experience increased ···【more】
Release date：2026-01-13Recommended：33
Capivasertib (trade name: Truqap) is an oral pan-AKT inhibitor. In combination w···【more】
Release date：2026-01-13Recommended：30
Capivasertib (trade name: Truqap) is the world’s first approved AKT inhibitor ta···【more】
Release date：2026-01-13Recommended：29
Capivasertib is an investigational serine/threonine kinase (AKT) inhibitor.Is Ca···【more】
Release date：2026-01-13Recommended：32
Capivasertib is an oral kinase inhibitor that targets all three isoforms of the ···【more】
Release date：2026-01-13Recommended：28
Drugs used to treat cancer are usually highly potent and may cause numerous side···【more】
Release date：2026-01-13Recommended：35
